Cellsonics
Making a Clean Break from Enzyme-Based Dissociation
Brian Quast, VP of Sales and Marketing
Tissue Dissociation Solution
Tissue Dissociation Solution is a laboratory reagent formulation used to enzymatically or chemically break down extracellular matrices and cell-cell junctions in biological tissues, enabling the isolation of viable single cells for downstream analysis, including flow cytometry, sequencing, and cell culture applications in biomedical research and clinical diagnostics workflows processes settings.
Solutions
Every day, scientists ponder a critical question: “Isn’t there a better way to dissociate tissue without harming cells?”
State of Industry
Tissue Dissociation's Expanding Role in Translational Medicine
The human organism represents an intricate cellular society, comprising trillions of cells, whose complex organization within tissues and organs was historically comprehended primarily from a macroscopic perspective. However, the forefront of medical advancement has transitioned from the macroscopic to the microscopic and is now shifting to single-cell resolution. Central to this transformative shift is a fundamental procedure: tissue dissociation. Its progression from a rudimentary scientific instrument to an indispensable component in sophisticated diagnostics and cell-based therapies signifies a paradigm shift in the methodology of disease diagnosis and treatment.
Deep Dive
Preserving Biological Fidelity in Tissue Dissociation
Tissue dissociation has become a much more important step in modern single-cell research than many laboratories once assumed. As scRNA-seq, flow cytometry and high-resolution cellular profiling become more central to translational and discovery research, scientists are paying closer attention to what happens to a sample before sequencing or analysis even begins. Increasingly, the concern is not just whether enough cells can be recovered, but whether the dissociation process itself changes the biology researchers are trying to measure.
Leadership Perspective
ICON [NASDAQ: ICLR]
The Significant Increase in Demand for Clinical Research Associates (CRAs)
Helen Yeardley, Executive Vice President
Much has changed since I started out as a CRA over 25 years ago – starting with the complexity of protocols for clinical trials, adding in new methodologies for monitoring data and patient safety, and culminating in the increased digitisation of clinical trials, to name just a few examples.
